An interventional study of Boston keratoprosthesis type 1 and Glaucoma drainage device in Corneal Transplantation and Glaucoma, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Glaucoma with a site in Canada — 17 open to participants now, 21 under way, 1 of them phase 3. Glaucoma · Canada.
Among the 85 studies in Glaucoma with a site in Canada, this one is the 44th largest by planned enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2014, is one of 43 with no phase, reaches primary completion later than 19 of the 20 other live ones, and was the 43rd registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →17 of the 85 studies in Glaucoma with a site in Canada are open now. Recruiting first, the newest first:
University of Waterloo · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Nova Scotia Health Authority · Sites in Canada
Ages 18+
University of Pennsylvania · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 8 · Phase 4 14
First in 1995; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 62 across the 68 interventional studies, 84 across the 15 observational. Of the 46 that completed or were terminated, 13 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 85 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 8 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Glaucoma with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT05924477University of PennsylvaniaGlaucoma Drainage Device and Endothelial Cell Loss Compare Trial | 2026-12 |
| NCT05180994Centre hospitalier de l'Université de Montréal (CHUM)Topical Infliximab in Eyes With Penetrating Keratoplasty | 2027-03-01 |
| NCT05024695iSTAR MedicalEvaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. | 2027-07 |
| NCT07739784McGill University Health Centre/Research Institute of the McGill University Health CentreThis Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling. | 2027-07-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 85 studies in Glaucoma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Boston keratoprosthesis (KPro) is a piece of specialized plastic that replace sick cornea (transparent structure at the front of the eye) in patients who have failed or those who are expected to have poor results with traditional corneal transplantation. While the Kpro can offer dramatic improvement in vision, it is also associated with several complications. Glaucoma (optic nerve damage due to high pressure inside the eye) is one of the most common complications after KPro surgery and can potentially cause irreversible vision loss. The implantation of a glaucoma drainage device (GDD), a tiny tube that drains the liquid inside the eye by bypassing the natural drainage system, is an effective option to lower the eye pressure in patients with KPro. Given the frequency and potentially devastating effects of glaucoma among KPro patients, some surgeons recommend to put in a GDD as a preventative measure. However, there is no consensus on when is the best timing to perform such surgery in relation to the Boston Kpro surgery.
Hypothesis:
For patients undergoing the Boston KPro surgery, implanting a GDD simultaneously, at the time of surgery, is more efficacious than at 6 months later, in the prevention of the progression of glaucoma and in maintaining better visual functions.
Methods:
The investigators aim to recruit 40 patients over 4 years. Recruited patients will be randomly assigned to 2 groups: 1) simultaneous GDD implantation at the Boston KPro surgery, and 2) GDD implantation 6 months after the Boston KPro surgery.
Once recruited, patients will be followed before the KPro surgery, postoperative day 1, week 1, month 1, 3, 6 and 12. Standard ophthalmological exam will be performed at each visit. Additional non-invasive glaucoma tests and evaluation (visual fields and optic nerve photo) will be performed on day 1, month 1, 3, 6 and 12.
For patients assigned to group 2, a GDD will be implanted 6 months after the KPro surgery. They will have additional follow-ups on post-GDD surgery day 1, week 1 and month 1.
Results of visual acuity, visual fields, optic nerve evaluation and complications will be compared between the two groups to determine the better timing of GDD implantation.
INTRODUCTION:
Glaucoma is a major problem for KPro candidates. Indeed, many diagnostic indications for KPro such as aniridia, chemical burns, trauma and repeated graft failure imply alteration of the iridocorneal angle, and consequently high intraocular pressure (IOP) and glaucoma. Accordingly, the prevalence of glaucoma before KPro surgery lies between 27% and 77%, with most studies showing a prevalence above 50%. The diagnosis and management of glaucoma is particularly challenging in the KPro population. Preoperatively, the measurement of IOP is possible through Goldmann tonometry and pneumotonometry but this measurement may be erroneous due to corneal scarring and irregularity. Furthermore, corneal opacification usually prevents visualization of the optic nerve head, and visual field assessment is not possible due to poor vision. Therefore, while glaucoma is often suspected in patients undergoing KPro, this diagnosis may be only confirmed postoperatively. While optic nerve head and visual field examination become possible following KPro surgery, the determination of IOP can only be accomplished through digital palpation. The shortcomings of this method, including its very poor inter- and intra-observer reliability, are well recognized. Because IOP reduction is the basis of glaucoma treatment, it is exceedingly difficult to manage glaucoma in the KPro population. In the face of such complexity, some KPro surgeons have suggested that Glaucoma Drainage Device (GDD) implantation could be performed during KPro surgery in all patients with marginal preoperative IOP control. With this approach, the GDD could prevent postoperative IOP rise and the need for subsequent surgical and medical intervention.
RATIONALE:
The decision to implant a GDD in a patient with pre-existing or prospective KPro must be weighed carefully. The insidious development or progression of glaucoma is the most common blinding complication of KPro implantation. Indeed, the course of glaucoma is a major determinant of KPro surgery prognosis and specifically of the visual result. On the other hand, complications associated with concomitant GDD and KPro surgeries may in themselves lead to severe and irreversible vision loss and thus, prevent the visual rehabilitation of these patients. With the increasing use of the KPro, it is important to evaluate the optimal timing of GDD implantation.
HYPOTHESIS:
For patients undergoing the Boston KPro surgery, implanting a GDD simultaneously, at the time of surgery, is more efficacious than waiting 6 months to implant a GDD, in the prevention of the progression of glaucoma and in maintaining better visual acuity and visual fields
OBJECTIVE:
METHODS:
Design: Single blind, prospective randomized controlled trial
Study Population: The duration of the study is 5 years, 4 years to recruit and 1 year to follow each patient. Forty consecutive patients (forty eyes) will be enrolled in this study. One eye of each patient will be included. The study protocol is approved by the Ethics Committee of CHUM. All patients will be informed about the design of the study and the procedure, and written informed consent will be obtained from all patients. Patient's eligibility for the study will be evaluated at the first consultation visit.
At the baseline study visit, patients will be randomized with a 1:1 allocation into two groups. Group 1 will comprise 20 patients undergoing KPro and simultaneous GDD while group 2 will include 20 patients undergoing KPro and then GDD 6 months later. Randomization schedule will be computer generated.
Prior to the surgery, a complete medical and ophthalmological history will be obtained from each patient. Patients will undergo a thorough ophthalmological evaluation, A-scan and B-scan ultrasound. The primary and concomitant pre-operative diagnoses are noted. The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique. The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2. Standard postoperative management will be followed. Follow-up visits will be performed on day 1, week 1, and months 1, 3, 6, and 12.
Study Procedures
Each patient's test results will be compiled in a table. Based on data available one month post-operatively, the investigators will decide whether there is evidence of glaucomatous optic neuropathy at this time (thereby likely reflecting presence of pre-existing glaucoma). Based on data gathered over 12 months, the investigators will decide whether or not the glaucoma has progressed through the course of the study.
All medical records, including operative protocol and progress notes, will be analyzed and data will be collected with respect to ophthalmic diagnosis of the operated eye. Patient demographics (age and gender), preoperative diagnosis, presence of pre-KPro glaucoma, surgical feasibility, retention of both GDD and KPro devices, short and long term complications of eyes who receive GDD will be studied. Patients who experience vision loss secondary to GDD complications such as tube occlusion, overfiltration, hypotony and choroidal hemorrhage will be analyzed in greater detail. Complications related to post-operative glaucoma will be evaluated. The extent of visual recuperation and the impact of glaucomatous optic nerve damage on the visual potential will be studied. Continued progression of glaucoma and the need for medical and surgical therapy will be determined.
STATISTICAL ANALYSIS:
The primary outcomes of this study, Visual Fields (Sita 24-2) and glaucomatous disc damage will be compared between both groups. Log rank test will be used to check the significance of differences between both groups. Pre- and post-best-corrected visual acuity (BCVA), as expressed in logMar units, will be compared in each group and plotted to demonstrate the evolution over time of the visual acuity in each group. Percentages of patients with fixation loss (BCVA worse than 1.30 logMar) at final visits from the two groups will also be compared.
The suitable time of GDD implantation will be determined by analyzing the visual outcome at the start and 1, 3, 6 and 12 months post-KPro and calculating the hazard on each time point. For this, time varying survival models - Cox and accelerated failure time (AFT) models will be applied according to their validity. The risk in both groups can be shown graphically by Kaplan Meier survival curve for loss of visual field and glaucomatous optic disc damage. Tests for statistical significance will be carried out at alpha=0.05.
SIGNIFICANCE:
The Boston KPro allows recovery of sight to patients with reversible corneal blindness. Glaucoma, a serious and sight threatening complication of KPro, may rob patients irreversibly and permanently of the sight they had recovered. The results of study will shed light on the most appropriate timing of glaucoma prevention and treatment. Hence, glaucoma will be treated in a timely fashion, preventing irreversible visual loss without subjecting patients to undue complications of glaucoma surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
Procedure: Boston keratoprosthesis type 1 · Procedure: Glaucoma drainage device
Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
Procedure: Boston keratoprosthesis type 1 · Procedure: Glaucoma drainage device
The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
Also known as: Boston KPro type 1
The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
Also known as: Ahmed Glaucoma Valve
Visual field mean deviation
Humphrey Visual Field 24-2 (SITA-Fast) (or Goldmann if poor vision/reliability)
Time frame: Change from baseline visual field mean deviation at 12 months
Disc Damage Likelihood Scale (DDLS) on clinical examination
Evaluation by a glaucoma specialist using the slit-lamp apparatus.
Time frame: Change from baseline DDLS on clinical examination at 12 months
Disc Damage Likelihood Scale (DDLS) on stereoscopic photographs of the optic nerve
Outcome assessed by a glaucoma specialist blinded to previous DDLS score
Time frame: Change from baseline DDLS on optic nerve photographs at 12 months
Incidence of ocular complications
All ocular complications reported by post-KPro 12 months
Time frame: 12 months after KPro
Change of visual acuity
Change of visual acuity compared between before and after surgery. The visual acuity is measured using the Snellen chart and expressed in logMAR.
Time frame: 12 months after KPro
Plan to share: No
Started May 2014 (actual). Primary completion is estimated for Dec 2028, 175 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 175 months is above that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Dec 2025 → Dec 2028 and completion Dec 2025 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre hospitalier de l'Université de Montréal (CHUM) →